Clinical Trial Update: High-dose Erythropoietin for Asphyxia and Encephalopathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating high-dose erythropoietin for neonatal encephalopathy due to birth asphyxia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birth Asphyxia
• Neonatal Encephalopathy

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neonatal Encephalopathy, Birth Asphyxia | Phase 3 | Status: COMPLETED | Results posted: 2023-01-30